Found 303 Results
Page 1 of 31
Refocusing R&D efforts as well as accelerating preclinical and clinical programs globally Cash position of €26.9 million as of June […]
09/13/2022
Paris (France), September 1st, 2022 – 8 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North[1]: ONXEO), a […]
09/01/2022
Last day of trading on the First North Growth market on November 8, 2022 Listing on Euronext Growth Paris remains […]
08/30/2022
Company to submit delisting request to Nasdaq Paris (France), August 17, 2022 – 08:00 pm CEST – Onxeo S.A. […]
08/17/2022
Paris (France), July 29, 2022 – 06:30 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO), a […]
07/29/2022
Paris (France), July 12, 2022 – 07:00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
07/12/2022
Onxeo to initiate its first phase 1b/2 trial in the United States in patients with solid tumors Paris (France), […]
06/30/2022
All resolutions voted in accordance with Board of Directors’ recommendations Khalil Barrage, Managing Director of Invus’ public equity investments division, […]
06/16/2022
Paris (France), April 28, 2022 – 6.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
04/28/2022
Watch the interview (in French)
04/20/2022
Page 1 of 31
